MCL1 and cancer: We further observed that DET/DETD-35 treatment for 6 h and 12 h induced increase in the full-length form of the anti-apoptotic protein Mcl-1; however, we also observed an increase in the Mcl-1 splicing variant Mcl-1S which antagonizes Mcl-1 and plays a pro-apoptotic role in cancer cells (Figure 5E) [38].